Silpa Gampala

Silpa Gampala

Auto-generated profile, based on publicly available information

Silpa Gampala

Department of Pediatrics, Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis IN, USA; Indiana University Simon Comprehensive Cancer Center, Indianapolis IN, USA

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2021 in Drug Discovery Today
Verified
Journal Article
Closed access
RCRachel A. Caston
Rachel A. Caston
SGSilpa Gampala
Silpa Gampala
LALee Armstrong
Lee Armstrong
RMRichard A. Messmann
Richard A. Messmann
MFMelissa L Fishel
Melissa L Fishel
MKMark Kelley
Mark Kelley

17 March 2021 in FASEB BioAdvances
Verified
Journal Article
Open access
PDF file
SGSilpa Gampala
Silpa Gampala
GZGuangJun Zhang
GuangJun Zhang
CCChun Ju Chang
Chun Ju Chang
JYJER-YEN YANG
JER-YEN YANG
Vismodegib, a Smoothened antagonist, is clinically approved for treatment of human basal cell carcinoma (BCC), in the clinical trials of medulloblastoma (MB) and other cancers. However, a significant...

10 March 2025 in Clinical Cancer Research
Verified
Journal Article
Closed access
DMDana K. Mitchell
Dana K. Mitchell
KBKylee Brewster
Kylee Brewster
SMStavriani C. Makri
Stavriani C. Makri
JKJaffar Khan
Jaffar Khan
EAEric A. Albright
Eric A. Albright
WCWade Clapp
Wade Clapp
Purpose: Malignant peripheral nerve sheath tumor (MPNST) is the leading cause of premature death among individuals with neurofibromatosis type 1 (NF1), and the transcriptional aberrations that precede malignant transformation and contribute to MPNST tumorigenesis remain poorly defined. Alterations involving CDKN2A and components of PRC2 have been implicated as early drivers of peripheral nerve sheath tumor (PNST) evolution, but these events do not occur in all MPNST. Accordingly, emerging data have begun to highlight the importance of molecular-based stratification to improve outcomes in patients with NF1–PNST. Experimental Design: In this study, we perform an integrated analysis of multiple, independent datasets obtained from human patients with NF1 to gain critical insights into PNST evolution and MPNST heterogeneity. Results: We show that delta-like noncanonical Notch ligand 1 (DLK1) is significantly increased in MPNST and provide evidence that DLK1 overexpression may precede histologic changes consistent with malignancy. In complementary analyses, we find that serum levels of DLK1 are significantly higher in both mice and humans harboring MPNST compared with those without malignancy. Importantly, although DLK1 expression is increased in MPNST overall, through the integration of multiple, independent datasets, we demonstrate that divergent levels of DLK1 expression distinguish MPNST subsets characterized by unique molecular programs and potential therapeutic vulnerabilities. Specifically, we show that overexpression of DLK1 is associated with the reactivation of embryonic signatures, an immunosuppressive microenvironment, and a worse overall survival in patients with NF1–MPNST. Conclusions: Collectively, our findings provide critical insights into MPNST tumorigenesis and support prospective studies evaluating the utility of DLK1 tissue and serum levels in augmenting diagnosis, risk assessment, and therapeutic stratification in the setting of NF1–PNST.